Literature DB >> 28189168

Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.

Margaret Barton-Burke1, Kathryn Ciccolini2, Maria Mekas2, Sean Burke3.   

Abstract

Cancer treatments usually have side effects of bone marrow depression, mucositis, hair loss, and gastrointestinal issues. Rarely do we think of skin side effects until patients have been treated successfully with epidermal growth factor receptor inhibitors (EGFRi). Those reactions include papulopustular rash, hair changes, radiation dermatitis enhancement, pruritus, mucositis, xerosis, fissures, and paronychia. This article discusses the common skin reactions seen when using EGFRi and presents an overview of skin as the largest and important organ of the body, including an overview of skin assessment, pathophysiology of the skin reactions, nursing care involved, and introduction to oncodermatology.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EGFRi (epidermal growth factor receptor inhibitors); Oncodermatology; Skin reactions

Mesh：

Substances：

Year:  2017        PMID： 28189168      PMCID： PMC5645079          DOI： 10.1016/j.cnur.2016.11.005

Source DB:  PubMed          Journal:  Nurs Clin North Am        ISSN： 0029-6465            Impact factor:   1.208


  19 in total

1.  Current unmet needs of cancer survivors: analysis of open-ended responses to the American Cancer Society Study of Cancer Survivors II.

Authors:  Mary Ann Burg; Gail Adorno; Ellen D S Lopez; Victoria Loerzel; Kevin Stein; Cara Wallace; Dinghy Kristine B Sharma
Journal:  Cancer       Date:  2015-01-12       Impact factor: 6.860

2.  Supportive care needs of individuals with lung cancer.

Authors:  Margaret I Fitch; Rose Steele
Journal:  Can Oncol Nurs J       Date:  2010

3.  Advanced lung cancer patients' experience with continuity of care and supportive care needs.

Authors:  Amna Husain; Lisa Barbera; Doris Howell; Rahim Moineddin; Andrea Bezjak; Jonathan Sussman
Journal:  Support Care Cancer       Date:  2012-12-29       Impact factor: 3.603

Review 4.  Mechanisms of cutaneous toxicities to EGFR inhibitors.

Authors:  Mario E Lacouture
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 5.  The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.

Authors:  Yevgeniy Balagula; Steven T Rosen; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2011-07-20       Impact factor: 11.527

6.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

Authors:  Barbara Melosky; Helen Anderson; Ronald L Burkes; Quincy Chu; Desiree Hao; Vincent Ho; Cheryl Ho; Wendy Lam; Christopher W Lee; Natasha B Leighl; Nevin Murray; Sophie Sun; Robert Winston; Janessa J Laskin
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

7.  Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists.

Authors:  Janelle Nicole Ruiz; Viswanath Reddy Belum; Patricia Creel; Allen Cohn; Michael Ewer; Mario E Lacouture
Journal:  Clin Genitourin Cancer       Date:  2014-05-16       Impact factor: 2.872

Review 8.  NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.

Authors:  Barbara Burtness; Milan Anadkat; Surendra Basti; Miranda Hughes; Mario E Lacouture; Joan S McClure; Patricia L Myskowski; Jennifer Paul; Clifford S Perlis; Leonard Saltz; Sharon Spencer
Journal:  J Natl Compr Canc Netw       Date:  2009-05       Impact factor: 11.908

9.  Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.

Authors:  Bret Wacker; Tina Nagrani; Jacqueline Weinberg; Karsten Witt; Gary Clark; Pablo J Cagnoni
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

Review 10.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603
View more
  7 in total

Review 1.  Pruritus Associated with Targeted Anticancer Therapies and Their Management.

Authors:  Jennifer Wu; Mario E Lacouture
Journal:  Dermatol Clin       Date:  2018-07       Impact factor: 3.478

Review 2.  Tyrosine kinase inhibitors in breast cancer (Review).

Authors:  George Iancu; Dragos Serban; Cristinel Dumitru Badiu; Ciprian Tanasescu; Mihai Silviu Tudosie; Corneliu Tudor; Daniel Ovidiu Costea; Anca Zgura; Raluca Iancu; Danut Vasile
Journal:  Exp Ther Med       Date:  2021-12-03       Impact factor: 2.447

Review 3.  Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.

Authors:  Jennifer Dine; RuthAnn Gordon; Yelena Shames; Mary Kate Kasler; Margaret Barton-Burke
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Apr-Jun

4.  Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China.

Authors:  Ruofei Du; Xin Wang; Lixia Ma; Leon M Larcher; Han Tang; Huiyue Zhou; Changying Chen; Tao Wang
Journal:  BMC Cancer       Date:  2021-02-28       Impact factor: 4.430

Review 5.  Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.

Authors:  Ruoning Yang; Yueyi Li; Hang Wang; Taolin Qin; Xiaomeng Yin; Xuelei Ma
Journal:  Mol Biomed       Date:  2022-03-04

6.  The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.

Authors:  Ruofei Du; Huashan Yang; Huiyue Zhou; Lixia Ma; Mikiyas Amare Getu; Changying Chen; Tao Wang
Journal:  BMC Cancer       Date:  2022-05-03       Impact factor: 4.638

7.  Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.

Authors:  Ru-Yu Lien; Heng-Hsin Tung; Shang-Laing Wu; Sophia H Hu; Ling-Chun Lu; Shu-Fen Lu
Journal:  Cancer Rep (Hoboken)       Date:  2021-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.